Institutional members access full text with Ovid®

Share this article on:

Future directions in therapeutic interventions for conjunctival inflammatory disorders

Pflugfelder, Stephen C; Stern, Michael E

Current Opinion in Allergy and Clinical Immunology: October 2007 - Volume 7 - Issue 5 - p 450–453
doi: 10.1097/ACI.0b013e3282ef69e3
Eye allergy

Purpose of review To review recent advances in pathogenesis and treatment of conjunctival inflammatory disorders.

Recent findings The conjunctiva becomes inflamed in a number of conditions, including allergy, atopy, dry eye, mucus membrane pemphigoid, Stevens-Johnson syndrome and surgical manipulation. Basic and clinical studies have identified a number of inflammatory mediators as potential therapeutic targets in these conditions. Additionally, new therapeutic agents and enhanced delivery systems have been evaluated.

Summary Increased understanding of the key mediators of conjunctival inflammation coupled with improved drug delivery methods are leading to more effective therapy for conjunctival inflammatory disorders.

aOcular Surface Center, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA

bBiological Sciences, Allergan, Inc., Irvine, California, USA

Correspondence to Stephen C. Pflugfelder, MD, Cullen Eye Insititute, 6565 Fannin, NC 205, Houston, TX 77030, USA fax: +1 713 798 1457; e-mail:

Copyright © 2007 Wolters Kluwer Health, Inc. All rights reserved.